Sign Up Today and Learn More About Alumis Stock
Invest in or calculate the value of your shares in Alumis or other pre-IPO companies through EquityZen's platform.
Alumis Stock (ALUM)
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
About Alumis Stock
Founded
2021
Headquarters
San Francisco, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
Alumis is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
Alumis Press Mentions
Stay in the know about the latest news on Alumis
Alumis (ALMS) Merges with ACELYRIN
finance • Jul 29, 2025
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
biospace • Jul 25, 2025
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
globenewswire • Jul 24, 2025
Appointments and advancements for July 16, 2025
bioworld • Jul 18, 2025
Alumis promotes Sanam Pangali to chief legal officer
thefly • Jul 15, 2025
Alumis Management
Leadership team at Alumis
Board of Directors
Alan Colowick
Board Member
Michael Rome
Join now and verify your accreditation status to gain access to:
- Alumis Current Valuation
- Alumis Stock Price
- Alumis Management
- Available deals in Alumis and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Alumis Cap Table and Funding History by Share Class and Liquidity Preferences
- Alumis Revenue and Financials
- Alumis Highlights
- Alumis Business Model
- Alumis Risk Factors
- Alumis Research Report from SACRA Research
Trading Alumis Stock
How to invest in Alumis stock?
Accredited investors can buy pre-IPO stock in companies like Alumis through EquityZen funds. These investments are made available by existing Alumis shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Alumis stock?
Shareholders can sell their Alumis stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
